Purchase channels for Tebentafusp-tebn

Tebentafusp-tebn) is currently the first and only drug in the new class of ImmTAC. As the first ImmTAC, tibenforx provides a new treatment option for select patients with unresectable or metastatic uveal melanoma. T cell-engaging immunotherapeutics mark impressive advances in the ability to target previously untreated diseases. Tebenforxo may be administered by continuous intravenous infusion15 to 20 minutes once weekly, recommended start at week The dose is 20 μg, and the dose is increased to 30 μg in the week 2 weeks, and to 68 μg in the week and thereafter.

Human leukocyte antigen (HLA)-a*02:01 is present in approximately45% of patients with uveal melanoma in the United States and Europe. Metastatic uveal melanoma is a tumor with high expression of glycoprotein 100, a new class of molecules known as immune-mobilizing monoclonal T-cell anticancer receptors (ImmTAC). Cell-redirecting bispecific fusion proteins, use engineered high-affinityT cell receptors to target specific proteins, including intracellular antigens, presented as peptidesHLA complexes on the target cell surface. Once ImmTAC molecules bind to specific peptide HLA complexes on the surface of target cells, they recruit and activate polyclonal T cells via CD3 to release cytokines and cytolytic mediators directed against the target cells.

The original drug of Tibenforsi is not currently on the market in China, nor has it been included in medical insurance. Domestic patients cannot yet purchase this drug. After Tebenforx is approved for marketing, there may be less price and other related information. For more drug information and specific prices, please consult a medical consultant.